

Boston Therapeutics

Innovators in Complex Carbohydrate Chemistry™


Presented by:
Ken Tasse, President, COO
(978)886-0421

Forward Looking Statements

Any statements about any possible future expectations, plans and prospects for the Company, including statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward looking statements, which are subject to the safe harbor for such statements in the Private Securities Litigation Reform Act of 1995. Future events could cause actual results to differ materially from those indicated by such statements. Reference is made to the factors discussed in the "Management Discussion and Analysis" and "Risk Factors" sections of the Company's most recent business plan or report filed with the Securities and Exchange Commission. The forward-looking statements herein represent the Company's views and possibilities as of the date of this presentation and should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements. For a more comprehensive risk disclosure we direct you to our web site www.bostonti.com

Mission Statement

To Develop and Commercialize
Drugs and Dietary Supplements
for Diabetes



Global Market Opportunity

Total Global Market = 554,000,000 people

Diabetes Category Sales= \$30 Billion

▶ Pre-diabetes

- 2007: 308 million people
- 2025 : 418 million

▶ Diabetes

- 2007: 246 million people
- 2025 : 380 million



International Diabetes Federation

Business Summary

Boston Therapeutics Inc. is a fully reporting company registered with the SEC



Patented pipeline of drug candidates based on proprietary chemistry
multiple revenue streams in large disease markets

SUGARDOWN™ validated in clinical trial to moderate post-meal elevation of glucose
product revenue funds future trials and pipeline

Experienced executive team and advisors can move products through FDA

Applied Carbohydrate Chemistry

David Platt, PhD, Co-founder



Editor of Two Books on Carbohydrate Drug Design and Specific Receptors. Inventor of numerous patents and author of many publications in peer-reviewed journals.

Successful Business Model Pronova BioPharma



REVENUE

active
pharmaceutical
ingredient as food
supplement

PRESCRIPTION

DRUG
FDA

MARKETING



PAZ320™


Safe, Non-toxic, Effective,
Convenient Drug Candidate
for Diabetes

Potentially superior to Acarbose©


Mechanism of Action

Inhibits Carbohydrate-Hydrolyzing Enzymes

Cross Section of Bowel




**Mannan
Polysaccharide**



Reduces Post-meal elevation of
Glucose in the Blood

Effect of PAZ320™ on Post-meal Blood Glucose



Moderates Sugar Levels

GI = Glycemic Index, a measure of the influence of carbohydrates on blood glucose levels

First Product to Market

Chewable **SUGARDOWN™**

Safe, Effective and
Convenient Product for
Glycemic Health.



Which One has Diabetes?



IPOXYN™

- Second-generation Hemoglobin-Based Oxygen Carrier (HBOC)
- New chemical entity (NCE)
- Safe
- Versatile
- Continuous IV administration
- GMP manufactured
- Stable for five years at room temperature
- Effective in animals



Intellectual Property Base

PAZ320 & SUGARDOWN™

US Patent # 5,527,770

Extraction method for neutrally charged polysaccharide similar to SugarDown manufacturing method

US Patent # 5,891,861

Acetylated Glucosamine which recognizes monosaccharides to act as acceptor. SugarDown is the acceptor; glucose is the metabolite.

US Patent # 5,681,923

SugarDown behaves as lectin-binding carbohydrate.

US Patent # 6,423,314

Identifying the characteristic sequence and three-dimensional structure of polysaccharide requirement for glucose binding capacity.

US Patent # 5,759,992

Extraction method for neutrally charged polysaccharide similar to SugarDown manufacturing method

Additional SUGARDOWN™ provisional Patent # 61,410,609

extraction, purification and composition of mannan polysaccharides

IPOXYN™

U.S. Provisional Appl. No. 61/285,281

HEMOGLOBIN COMPOSITIONS AND METHODS OF USE



Product Pipeline

Drug Candidate	Indication	Status
PAZ320	Diabetes	Phase I trial completed 6/11; Phase II trial to commence 1/12
IpoxyTM	Next Generation Hemoglobin-Based Oxygen Carrier (Human)	Phase III trial to commence in 2012
OxyFexTM	Next Generation Hemoglobin-Based Oxygen Carrier (Vet)	Phase III trial to commence in 2012
BTI-9	Crohn's Disease	In preclinical
PazametTM	Diabetes	In preclinical
OTC Candidate	Indication	Status
SugarDownTM	Blood Glucose Control	FDA claims accepted 2010; product available
BTI-10	Lipid/Cholesterol Management	In Development
BTI-11	Intestinal Health	In Development
BTI-12	Oral Probiotic	In Development

Clinical Trials Strategy

PAZ320 and SUGARDOWN™

- **Safety, Efficacy / Blood Glucose Only**
 - Healthy Individuals: 10 volunteers
(COMPLETED JUNE 2011)
- **Disease Claim / Blood Glucose Only**
 - Type 1 & 2 Diabetics : 24 Patients
- **Disease Claim / Multiple Markers**
 - Type 1 & 2 Diabetics: 300 Patients

Marketing

SUGARDOWN™

•China

- Advance Pharmaceutical Co, Hong Kong**
Licensing and Manufacturing Agreement

•U.S.

- Strategic Marketing Alliance**
 - Direct Response radio/TV
 - Search Engine Optimization
 - Web-based marketing
 - Retail

Management

David Platt, Ph.D., Chairman and CEO / CFO

From 2001 to 2009, Dr. Platt was the founder, CEO and Chairman of Pro-pharmaceuticals, Inc. From 1995 to 2000, Dr. Platt the founder, CEO and Chairman of SafeScience Inc.,. From 1992 to 1995, Dr. Platt was the founder, CEO and Chairman of International Gene Group, Inc., the predecessor company to SafeScience. Dr. Platt received a Ph.D. in Chemistry in 1988 from Hebrew University in Jerusalem Dr. Platt has published peer-reviewed articles and holds many patents and edited two books, primarily in the field of carbohydrate chemistry.

Kenneth A Tassej Jr., President and COO

Mr. Tassej was President, CEO and co-founder of Boston Therapeutics, Inc., a New Hampshire corporation, from June 2009 until its acquisition by the Company in November 2010. From March 2007 thru March 2009 Mr. Tassej was President of TKCI, a consultant for commercial finance projects. From March 2005 thru June 2007 Mr. Tassej was President of Liberty Shore LLC, a consultant to businesses and commercial and residential lenders. Prior, Mr. Tassej consulted for businesses in mortgage, radiology software, advertising and retail. Mr. Tassej has 25 years business experience including operations, management, and sales.

Carl Lueders, Audit Committee Chairman

Carl Lueders, a Director of the Company since September 2009, has a broad range of experience in finance, operations, short- and long-term planning, forecasting, performance measurement, SEC reporting, and controls. He was most recently Chief Financial Officer (CFO) for Pro-Pharmaceuticals and before that CFO for R.F. Morse & Son, a privately held agri-based company. Previously, he was Interim Chief Executive Officer at Brine, a privately held manufacturer and distributor of sports equipment. Mr. Lueders spent 22 years with publicly held Polaroid in finance and planning roles, including Vice President and Controller, Treasurer and Acting Chief Financial Officer. Earlier in his career, Mr. Lueders was a Senior Auditor with Arthur Andersen. He is a CPA and received his B.A. in Economics from the University of Massachusetts at Amherst and his M.B.A. from Babson College.

Joan Sellers, Ph.D., Chief Technology Officer

Dr. Sellers joined Boston Therapeutics in December 2010 as Chief Technology Officer. Dr. Sellers brings over 20 years of experience in the biotechnology industry and has been involved in numerous efforts in drug discovery and technology development. She most recently served as Director of Development for Targeted Cell Therapies, from 2008 to 2010. From 1999 to 2006, Dr. Sellers founded and served as CEO of Vasculogic, a biotech start-up in the diabetes sector, and then as CEO of Citizens Pharmaceuticals, a non-profit pharmaceutical company.

Dr. Sellers was a research fellow in the Department of Nephrology at Beth Israel Deaconess Medical Center from 1995 to 1998. Prior to this, from 1990 to 1994, Dr. Sellers was a scientist at Transkaryotic Therapies (now Shire). From 1985 to 1990, Dr. Sellers was a postdoctoral fellow in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. Dr. Sellers earned her Ph.D. in Molecular Biology in 1985 from Albany State University.

Yehuda E Inbar, Vice President of IT/Media

Mr. Inbar has been responsible for developing major online media projects for Microsoft, HP, Intel, AT&T and other major corporations, From 1997 to 2009, he was Information Solutions Architect and 3D Expert with Show & Tell, Inc. In 1988, Mr. Inbar founded and continues to serve as President of 3DMedia Network.

Medical Advisory Board

**Dr. Hanna Chen-Walden, M.D. Advisor,
Medical Director for Safety**

Endocrinologist and expert in diabetes.

**Dr. Bruce Silver, M.D., Advisor, Medical
Director, Independent Consultant**

Dr. Silver has 20 years of clinical oncology practice. Dr. Silver is a Board-certified medical oncologist, fellow of the American College of Physicians, and member of the American Society of Clinical Oncology.

10,000,000 Registered Shares

As filed with the Securities and Exchange Commission on April 15, 2011

Registration No. 333-164785

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

POST-EFFECTIVE AMENDMENT NO. 1
to
FORM S-1

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

BOSTON THERAPEUTICS, INC.

(Name of issuer in its charter)

Business Summary

Boston Therapeutics Inc. is a fully reporting company, registered with the SEC

Patented pipeline of drug candidates based on proprietary chemistry
multiple revenue streams in large disease markets

SUGARDOWN™ validated in clinical trial to moderate post-meal elevation of glucose
product revenue funds future trials and pipeline
multi-billion dollar product in diabetes sector
PAZ320 follow-on drug application

Experienced executive team and advisors
can move products through FDA

